Skip to main content
Premium Trial:

Request an Annual Quote

IsoPlexis Inks Swiss Distribution Deal With Bucher Biotech

NEW YORK – Single-cell proteomics firm IsoPlexis said Tuesday it has entered into an exclusive agreement with Swiss life science tools distributor Bucher Biotec.

The agreement will allow Branford, Connecticut-based IsoPlexis to expand sales of its IsoLight and IsoSpark proteomics platforms into Switzerland.

The deal adds to recent agreements IsoPlexis has inked for distribution in countries including Singapore, Malaysia, China, Taiwan, Japan, South Korea, Spain, and Portugal.

"We are excited to partner with Bucher Biotec to further expand the reach of our unique solutions," Peter Siesel, IsoPlexis' chief commercial officer, said in a statement. "Our functional proteomics platform accelerates the development of personalized, curative medicines across a range of diseases and research disciplines. With this partnership, we are excited to see our usership grow even further."

Financial and other terms of the agreement were not disclosed.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.